Teleflex Incorporated (TFX)

$203.01

+4.28

(+2.15%)▲

Market is closed - opens 7 PM, 06 May 2024

Insights on Teleflex Incorporated

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 710.93M → 773.90M (in $), with an average increase of 2.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 137.14M → 31.10M (in $), with an average decrease of 77.3% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 25.1% return, outperforming this stock by 46.4%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 36.5% return, outperforming this stock by 87.0%

Performance

  • $199.12
    $206.49
    $203.01
    downward going graph

    1.92%

    Downside

    Day's Volatility :3.57%

    Upside

    1.68%

    downward going graph
  • $177.07
    $274.76
    $203.01
    downward going graph

    12.78%

    Downside

    52 Weeks Volatility :35.55%

    Upside

    26.11%

    downward going graph

Returns

PeriodTeleflex IncorporatedSector (Health Care)S&P500
3 Months
-16.83%
-1.1%
3.7%
6 Months
-4.7%
10.5%
17.7%
1 Year
-21.3%
5.4%
24.0%
3 Years
-50.53%
14.4%
23.0%

Highlights

Market Capitalization
9.9B
Book Value
$94.41
Dividend Share
1.36
Dividend Yield
0.64%
Earnings Per Share (EPS)
7.56
PE Ratio
27.93
PEG Ratio
2.48
Wall Street Target Price
264.5
Profit Margin
11.98%
Operating Margin TTM
12.7%
Return On Assets TTM
4.34%
Return On Equity TTM
8.45%
Revenue TTM
3.0B
Revenue Per Share TTM
63.31
Quarterly Revenue Growth YOY
2.1%
Gross Profit TTM
1.6B
EBITDA
743.7M
Diluted Eps TTM
7.56
Quarterly Earnings Growth YOY
-0.6
EPS Estimate Current Year
13.73
EPS Estimate Next Year
15.26
EPS Estimate Current Quarter
3.26
EPS Estimate Next Quarter
3.12

Analyst Recommendation

Hold
    47%Buy
    52%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Teleflex Incorporated(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
10
10
12
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 30.29%

Current $203.01
Target $264.50

Company Financials

FY18Y/Y Change
Revenue
2.4B
↑ 14.07%
Net Income
200.8M
↑ 31.65%
Net Profit Margin
8.2%
↑ 1.09%
FY19Y/Y Change
Revenue
2.6B
↑ 6.0%
Net Income
461.5M
↑ 129.81%
Net Profit Margin
17.78%
↑ 9.58%
FY20Y/Y Change
Revenue
2.5B
↓ 2.24%
Net Income
335.3M
↓ 27.34%
Net Profit Margin
13.22%
↓ 4.56%
FY21Y/Y Change
Revenue
2.8B
↑ 10.74%
Net Income
485.4M
↑ 44.75%
Net Profit Margin
17.28%
↑ 4.06%
FY22Y/Y Change
Revenue
2.8B
↓ 0.66%
Net Income
363.1M
↓ 25.18%
Net Profit Margin
13.01%
↓ 4.27%
FY23Y/Y Change
Revenue
3.0B
↑ 6.57%
Net Income
356.3M
↓ 1.88%
Net Profit Margin
11.98%
↓ 1.03%
Q3 FY22Q/Q Change
Revenue
686.8M
↓ 2.52%
Net Income
101.9M
↓ 3.43%
Net Profit Margin
14.84%
↓ 0.14%
Q4 FY22Q/Q Change
Revenue
758.0M
↑ 10.37%
Net Income
78.6M
↓ 22.87%
Net Profit Margin
10.37%
↓ 4.47%
Q1 FY23Q/Q Change
Revenue
710.9M
↓ 6.21%
Net Income
76.7M
↓ 2.34%
Net Profit Margin
10.8%
↑ 0.43%
Q2 FY23Q/Q Change
Revenue
743.3M
↑ 4.55%
Net Income
111.3M
↑ 45.07%
Net Profit Margin
14.98%
↑ 4.18%
Q3 FY23Q/Q Change
Revenue
746.4M
↑ 0.42%
Net Income
137.1M
↑ 23.18%
Net Profit Margin
18.37%
↑ 3.39%
Q4 FY23Q/Q Change
Revenue
773.9M
↑ 3.69%
Net Income
31.1M
↓ 77.32%
Net Profit Margin
4.02%
↓ 14.35%
FY18Y/Y Change
Total Assets
6.3B
↑ 1.56%
Total Liabilities
3.7B
↓ 0.35%
FY19Y/Y Change
Total Assets
6.3B
↑ 0.51%
Total Liabilities
3.3B
↓ 10.9%
FY20Y/Y Change
Total Assets
7.2B
↑ 13.36%
Total Liabilities
3.8B
↑ 14.58%
FY21Y/Y Change
Total Assets
6.9B
↓ 3.93%
Total Liabilities
3.1B
↓ 18.32%
FY22Y/Y Change
Total Assets
6.9B
↑ 0.82%
Total Liabilities
2.9B
↓ 6.77%
FY23Y/Y Change
Total Assets
7.5B
↑ 8.73%
Total Liabilities
3.1B
↑ 6.38%
Q3 FY22Q/Q Change
Total Assets
6.8B
↑ 0.39%
Total Liabilities
2.9B
↓ 0.56%
Q4 FY22Q/Q Change
Total Assets
6.9B
↑ 2.52%
Total Liabilities
2.9B
↑ 1.51%
Q1 FY23Q/Q Change
Total Assets
6.9B
↓ 0.15%
Total Liabilities
2.8B
↓ 3.39%
Q2 FY23Q/Q Change
Total Assets
6.9B
↓ 0.32%
Total Liabilities
2.7B
↓ 4.52%
Q3 FY23Q/Q Change
Total Assets
7.5B
↑ 8.67%
Total Liabilities
3.2B
↑ 18.61%
Q4 FY23Q/Q Change
Total Assets
7.5B
↑ 0.52%
Total Liabilities
3.1B
↓ 2.77%
FY18Y/Y Change
Operating Cash Flow
437.4M
↑ 4.17%
Investing Cash Flow
-196.4M
↓ 89.28%
Financing Cash Flow
-206.4M
↓ 118.09%
FY19Y/Y Change
Operating Cash Flow
439.5M
↑ 0.49%
Investing Cash Flow
-73.5M
↓ 62.58%
Financing Cash Flow
-418.8M
↑ 102.89%
FY20Y/Y Change
Operating Cash Flow
436.4M
↓ 0.71%
Investing Cash Flow
-837.8M
↑ 1040.14%
Financing Cash Flow
455.2M
↓ 208.67%
FY21Y/Y Change
Operating Cash Flow
651.4M
↑ 49.27%
Investing Cash Flow
156.7M
↓ 118.71%
Financing Cash Flow
-715.8M
↓ 257.27%
FY22Y/Y Change
Operating Cash Flow
342.1M
↓ 47.48%
Investing Cash Flow
-257.9M
↓ 264.57%
Financing Cash Flow
-217.5M
↓ 69.61%
Q3 FY22Q/Q Change
Operating Cash Flow
142.4M
↑ 259.52%
Investing Cash Flow
-12.6M
↓ 60.21%
Financing Cash Flow
-25.6M
↓ 83.35%
Q4 FY22Q/Q Change
Operating Cash Flow
98.2M
↓ 31.01%
Investing Cash Flow
-257.9M
↑ 1941.32%
Financing Cash Flow
-17.1M
↓ 33.08%
Q1 FY23Q/Q Change
Operating Cash Flow
84.1M
↓ 14.4%
Investing Cash Flow
-21.9M
↓ 91.51%
Financing Cash Flow
-93.6M
↑ 446.26%
Q2 FY23Q/Q Change
Operating Cash Flow
86.1M
↑ 2.42%
Investing Cash Flow
-7.3M
↓ 66.53%
Financing Cash Flow
-92.4M
↓ 1.27%
Q3 FY23Q/Q Change
Operating Cash Flow
201.6M
↑ 134.17%
Investing Cash Flow
-57.7M
↑ 687.26%
Financing Cash Flow
462.0M
↓ 600.04%

Technicals Summary

Sell

Neutral

Buy

Teleflex Incorporated is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Teleflex Incorporated
Teleflex Incorporated
-6.35%
-4.7%
-21.3%
-50.53%
-32.1%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-1.81%
37.55%
25.09%
36.46%
125.0%
Resmed Inc.
Resmed Inc.
14.95%
41.01%
-6.33%
12.66%
92.65%
Becton, Dickinson And Company
Becton, Dickinson And Company
-4.67%
-9.42%
-7.48%
-6.04%
-1.61%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-7.36%
9.61%
-0.93%
11.08%
197.3%
Alcon Ag
Alcon Ag
-6.17%
7.59%
7.98%
13.61%
33.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Teleflex Incorporated
Teleflex Incorporated
27.93
27.93
2.48
13.73
0.08
0.04
0.01
94.41
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
67.57
67.57
7.13
6.28
0.16
0.08
NA
39.37
Resmed Inc.
Resmed Inc.
30.38
30.38
1.75
7.4
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
53.75
53.75
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
49.01
49.01
6.72
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
40.22
40.22
4.59
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Teleflex Incorporated
Teleflex Incorporated
Hold
$9.9B
-32.1%
27.93
11.98%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$133.0B
125.0%
67.57
27.16%
Resmed Inc.
Resmed Inc.
Buy
$27.0B
92.65%
30.38
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.6B
-1.61%
53.75
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$28.2B
197.3%
49.01
20.12%
Alcon Ag
Alcon Ag
Buy
$38.9B
33.62%
40.22
10.3%

Institutional Holdings

  • T. Rowe Price Investment Management,Inc.

    14.95%

  • Vanguard Group Inc

    11.58%

  • HHG PLC

    10.25%

  • BlackRock Inc

    9.10%

  • Morgan Stanley - Brokerage Accounts

    5.86%

  • Wellington Management Company LLP

    5.30%

Corporate Announcements

  • Teleflex Incorporated Dividends March,2024

    In the quarter ending March,2024. Teleflex Incorporated has declared dividend of $0.34

    Read More

Company Information

teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. headquartered in wayne, pa, teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.

Organization
Teleflex Incorporated
Employees
14500
CEO
Mr. Liam J. Kelly
Industry
Health Technology

Discover More

FAQs